Selected article for: "psoriasis area and severity index"

Author: Ang, E; Hadjieconomou, S; Kalavala, M
Title: Brodalumab-induced subacute cutaneous lupus erythematosus.
  • Cord-id: dz0fbf27
  • Document date: 2021_1_28
  • ID: dz0fbf27
    Snippet: A 51-year-old male with a background of chronic plaque psoriasis was started on brodalumab after experiencing deterioration of his skin condition. His Dermatology Life Quality Index (DLQI) was 13 and Psoriasis Area and Severity Index (PASI) was 19.2 despite being on ixekizumab and methotrexate. He had previously been treated with apremilast, fumaric acid esters, infliximab, adalimumab, secukinumab and ustekinimab.
    Document: A 51-year-old male with a background of chronic plaque psoriasis was started on brodalumab after experiencing deterioration of his skin condition. His Dermatology Life Quality Index (DLQI) was 13 and Psoriasis Area and Severity Index (PASI) was 19.2 despite being on ixekizumab and methotrexate. He had previously been treated with apremilast, fumaric acid esters, infliximab, adalimumab, secukinumab and ustekinimab.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1
    Co phrase search for related documents, hyperlinks ordered by date